Sort   by:  
 Page size 
UnknownIntermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Not available
S-EPMC3159416 | biostudies-literature
UnknownAddition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
Not available
S-EPMC3159415 | biostudies-literature
UnknownCommon variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk.
Not available
S-EPMC4747430 | biostudies-literature
UnknownCost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema.
Not available
S-EPMC9896372 | biostudies-literature
UnknownEffects of medical therapies on retinopathy progression in type 2 diabetes.
Not available
S-EPMC4026164 | biostudies-literature
UnknownDeep learning enhanced ALPS reveals genetic and environmental factors of brain glymphatic function.
Not available
S-EPMC12878677 | biostudies-literature
UnknownAflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
Not available
S-EPMC9714135 | biostudies-literature
UnknownPlasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
Not available
S-EPMC6568257 | biostudies-literature
UnknownAflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
Not available
S-EPMC4422053 | biostudies-literature
UnknownFour-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
Not available
S-EPMC10408259 | biostudies-literature
Sort   by:  
 Page size